about
PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms iOverdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and managementAsenapine: a novel psychopharmacologic agent with a unique human receptor signaturePimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disordersThe pharmacology and toxicology of atypical antipsychotic agents.Priapism associated with zuclopenthixol.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetMetabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.Asenapine augmentation in bipolar disorders: a case series.A traditional Korean multiple herbal formulae (Yuk-Mi-Jihwang-Tang) attenuates acute restraint stress-induced brain tissue oxidation.Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats.Intractable hiccups (singultus) abolished by risperidone, but not by haloperidolExposure to Kynurenic Acid during Adolescence Increases Sign-Tracking and Impairs Long-Term Potentiation in Adulthood.Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil.Prescribing conventional antipsychotics at two Veterans Administration hospitals: are there geographical differences?Tardive nocturnal akathisia due to clozapine treatment.Risperidone-to-methylphenidate switch reaction in children: three cases.Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting.
P2860
Q24621061-4B56886B-50F8-46E7-859E-8A5CDBEEF1C8Q28268128-F748F0BD-4F5A-47A5-80D2-61FDBF5DE6C5Q28270767-0AF76F1C-8B5F-467A-8CD0-C8163FC2FEECQ28302151-A5AF921D-B254-40F4-8A2B-596D30E51091Q34235349-1222EA62-19F0-4809-AB43-74862398E929Q34648613-539832F0-959B-42B0-A310-317707E7A618Q35200831-73C6E0A6-972F-4D3D-9853-54F852D42D7AQ36474147-9C6AC971-2C3D-4953-A864-59E2312BBDF8Q36868401-EBD57BA4-F0B3-4CDC-9BE3-56CE073949C2Q38997636-016F1D3B-80DD-4FCE-917D-CA2E8EAB5C80Q39427187-62CDD6EF-BBC9-48D4-A82F-70C8AC87CF3CQ41973068-B55902D5-A51B-4868-993F-DDF6635C77AAQ43092673-770420E6-8BCC-460F-BAEE-BD64804C71DAQ44343611-AE27799F-503B-44A7-A1B8-98616FAA6B3FQ45333453-8A641397-C379-4C39-BEC8-E8D62B0E1459Q46767141-24B1B861-43CB-4AE8-BBBE-3AFD645369BDQ50908416-4E37804C-B456-45E7-B8B6-EAC1F67926ACQ51951486-AD9DDDEF-362D-4108-8D62-069DA869444B
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A comparative review of new antipsychotics.
@ast
A comparative review of new antipsychotics.
@en
type
label
A comparative review of new antipsychotics.
@ast
A comparative review of new antipsychotics.
@en
prefLabel
A comparative review of new antipsychotics.
@ast
A comparative review of new antipsychotics.
@en
P2860
P1476
A comparative review of new antipsychotics.
@en
P2093
P2860
P304
P356
10.1177/070674379904400303
P407
P577
1999-04-01T00:00:00Z